Introduction: Selective serotonin and norepinephrine reuptake inhibitors (SNRI) are among
the most prescribed antidepressants, and dose escalation is a frequently applied strategy …

Abstract Background Quality of Life (QoL) is an important outcome in mental disorders. We
investigated whether antidepressant pharmacotherapy improved QoL vs. placebo among …

Objective The goal of this meta-analysis was to quantify the risk of dry mouth associated with
commonly prescribed antidepressant agents and examine the potential implications of …

Major depressive disorder (MDD) and other mental health issues pose a substantial burden
on the workforce. Approximately half a million Canadians will not be at work in any week …

Background The bidirectional association between Major Depressive Disorder (MDD) and
obesity suggests that body mass index (BMI) at the baseline could influence remission rates …

Objectives: To evaluate the short-term efficacy and safety of desvenlafaxine (25–50 mg/d)
compared with placebo in children and adolescents with major depressive disorder (MDD) …

Importance Placebo is the only substance systematically evaluated across common
psychiatric diagnoses, but comprehensive cross-diagnostic comparisons are lacking …

This randomized, open label, prospective, observational study compared clinical efficacy,
safety alongwith plasma BDNF levels in outpatients of depression treated with fluoxetine …

Objective This study aimed to compare the efficacy and safety of escitalopram, vortioxetine,
and desvenlafaxine for acute treatment of major depressive disorder (MDD) with cognitive …

Objective: To evaluate the short-term efficacy and safety of desvenlafaxine versus placebo in
the treatment of children and adolescents with major depressive disorder (MDD). Methods …